Understanding why some people with HIV can temporarily control the virus without medication
Delineating the viro-immunological factors contributing to transient HIV control during consecutive analytical treatment interruptions
This project looks at why a small number of people with HIV can keep the virus at low levels for months after stopping their medication.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Sydney NIH-funded |
| Lab location | 1 site (Sydney, Australia) |
| Project ID | NIH-11141241 on NIH RePORTER |
What this research studies
The project focuses on people living with HIV who, after stopping their antiretroviral therapy (ART), can temporarily control the virus without medication. Researchers are looking into the specific viral and immune system factors that allow these individuals to maintain low levels of HIV for an extended period. They will use advanced genetic sequencing to study the virus in blood samples from participants who experienced this temporary control during a previous clinical trial. By comparing the genetic makeup of the virus and the body's immune response, they hope to uncover the mechanisms behind this unique ability.
Who could benefit from this research
Good fit: Ideal candidates are people living with HIV who have previously participated in studies involving analytical treatment interruptions and demonstrated transient viral control.
Not a fit: Patients who have never been on ART or who experience rapid viral rebound after stopping ART may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new strategies for long-term HIV control or even a cure, reducing the need for daily medication.
How similar studies have performed: Previous studies have identified some factors linked to delayed viral rebound, and preliminary findings from the PULSE clinical trial suggest that distinct HIV populations emerge during transient control, indicating a novel area of investigation.
Where this research is happening
Sydney, Australia
- University of Sydney — Sydney, Australia (Active)
Researchers
- Principal investigator: Palmer, Sarah Elizabeth — University of Sydney
- Study coordinator: Palmer, Sarah Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.